Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Summary

This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.

Timeline

Start

2018-02-16

Primary completion

2020-07-16

Completion

2020-07-16

Outcome

Outcome not reported

Stopped (Business): “The Relamorelin program is being terminated solely based on a business decision”

Drugs

Indications